Riluzole

CNS Drug Reviews

Volumn 2, Issue 1, 1996, Pages 40-51

  Mantz, Jean ^a,b  

^a BICHAT HOSPITAL   (France)

^b INSERM   (France)

Author keywords

amyotryophic lateral sclerosis; anesthetic; anticonvulsant; anxiolytic; brain ischemia; glutamate; neurotransmitter release; neurotransmitter uptake; riluzole; sodium channels

Indexed keywords

1,3 DIETHYL 8 PHENYLXANTHINE; 2 AMINO 15 PHOSPHONOPENTANOIC ACID; 4 AMINOBUTYRIC ACID; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; APOMORPHINE; ASPARTIC ACID; BACLOFEN; CYCLOHEXYLADENOSINE; DICHLOROKYNUREMIC ACID; EXCITATORY AMINO ACID; FLUNITRAZEPAM; GLUTAMIC ACID; HALOPERIDOL; HARMALINE; ION CHANNEL; KARINIC ACID; MUSCIMOL; N METHYL BETA CARBOLINE 3 CARBOXAMIDE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; PHENCYCLIDINE; QUISQUALIC ACID; RADIOLIGAND; RILUZOLE; STRYCHNINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL MODEL; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; HUMAN; NEUROTRANSMISSION; NONHUMAN; REVIEW;

EID: 0029868864     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1996.tb00289.x     Document Type: Review

References (66)

1. Alaoui F, Pratt J, Menetrier F, Stutzmann JM, Court L. Riluzole protects the dentate gyrus of gamma-irradiated immature rats. In: Jolles G, Stuzmann JM, eds. Neurodegenerative Diseases. London (UK): Academic Press, 1994:215-221.
2. Barbeito L, Chéramy A, Godeheu G, Desce JM, Glowinski J. Glutamate receptors of the quisqualate-kainate subtype are involved in the presynaptic regulation of dopamine release in the cat caudate nucleus in vivo. Eur J Neurosci 1990;2:304-311.
3. Baruch P, Artaud F, Godeheu G, Barbeito L, Glowinski J, Chéramy A. Substance P and neurokinin A regulate by different mechanisms dopamine release from dendrites and nerve terminals of the nigrostriatal dopaminergic neurons. Neuroscience 1998;25:889-898.
4. Ben-Ari Y, Anikstsztejn L, Bregetovski P. Protein kinase C modulation of NMDA currents: An important link for LTP induction. Trends Neurosci 1992;15:333-339.
5. Benavides J, Camelin JC, Mitrani N, et al. 2-amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory aminoacid neurotransmission. II. Biochemical properties. Neuropharmacology 1985;26: 1085-1092.
6. Benoit E, Escande D. Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre. Pflügers Arch 1991;419:603-609.
7. Benoit E, Escande D. Fast K channels are more sensitive to riluzole than slow K channels in myelinated nerve fibre. Pflügers Arch 1993;422:536-538.
8. Bensimon G, Lacomblez L, Meininger V and the ALS/riluzole study group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-591.
9. Biggio G, Guidotti A. Climbing fiber activation and 3,5′-cyclic guanosine monophosphate (cGMP) content in cortex and deep nuclei of cerebellum. Brain Res 1976;107:365-373.
10. Boening JA, Kass ID, Cottrell JE, Chambers G. The effect of blocking sodium influx on anoxic damage in the rat hippocampal slice. Neuroscience 1989;33:263-268.
11. +-induced increase in striatal extracellular dopamine in rats in vivo. NeuroReport 1994;5:2157-2160.
12. Burgerman RS. Riluzole in amyotrophic lateral sclerosis (letter). N Engl J Med 1994;331:273.
13. 3H]aspartate release in rodents. J Neurochem 1985;45:370-381.
14. Chéramy A, Romo R, Godeheu G, Baruch P, Glowinski J. In vivo presynaptic control of dopamine release in the cat caudate nucleus: II. Facilitatory or inhibitory influence of L-glutamate. Neuroscience 1986;19: 1081-1090.
15. Chéramy A, Barbeito L, Godeheu G, Glowinski J. Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett 1992;147:209-212.
16. Choi DW, Rothman SM. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci 1990;13:171-182.
17. Debono MW, Escande D. Electrophysiological studies of the effects of riluzole on Purkijné cells in cerebellar slices. Br J Pharmacol 1989;7:SP10.
18. Debono MW, Le Guern J, Canton T, Doble A, Pradier L. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol 1993;235:283-289.
19. Dessi F, Ben-Ari Y, Charriaut-Marlangue C. Riluzole prevents anoxic injury in cultured cerebellar granule neurons. Eur J Pharmacol 1993;250:325-328.
20. Doble A. The pharmacology and mechanisms of action of riluzole. Neurology (in press).
21. 3H]-aspartate release from cultured cerebellar granule cells. Neurosci Lett 1992;140: 251-254.
22. Doble A, Perrier ML. Pharmacology of excitatory amino acid receptor coupled to inositol phosphate metabolism in neonatal striatum. Neurochem Int. 1989;15:1-9.
23. 3H]-GABA from cultured mouse cerebral cortex interneurons. J Neurosci 1987;7:2910-2916.
24. Franks NP, Lieb WR. Molecular and cellular mechanisms of general anesthesia. Nature 1994;367:607-614.
25. Girdlestone D, Coston A, Dupuy A, Roy-Contancin L, Escande D. Riluzole antagonizes excitatory amino acid-evoked firing in rat facial motoneurones in vivo. Br J Pharmacol 1989;97:583P.
26. Globus MIT, Busto R, Dietrich WD, Martinez E, Valdes I, Ginsberg MD. Effect of ischemia on the in vivo release of striatal dopamine, glutamate, and gamma amino butyric acid studied by intracerebral microdialysis. J Neurochem 1988;51:1455-1463.
27. Globus MIT, Ginsberg MD, Harik SI, Busto R, Dietrich WD. Role of dopamine in ischemic striatal injury: Metabolic evidence. Neurology 1987;37:1712-1719.
28. Hebert T, Drapeau P, Pradier L, Dunn RJ. Block of the rat brain IIA sodium channel alpha subunit by the neuroprotective drug riluzole. Mol Pharmacol 1994;45:1055-1060.
29. Hiramatsu M, Cho AK. Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine. Psychopharmacology 1988;96:s325.
30. Hubert JP, Delumeau JC, Glowinski J, Prémont J, Doble A. Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: Evidence for a dual mechanism of action. Br J Pharmacol 1994;113:261-267.
31. 3H] -aspartate release from cerebellar granule cells. Neurosci Lett 1989;96:345-350.
32. Jones-Humble SA, Morgan PF, Cooper BR. The novel anticonvulsant lamotrigine prevents dopamine depletion in C57 black mice in the MPTP animal model of Parkinson's disease. Life Sci 1994;54:245-252.
33. Koek W, Colpaert FC. Use of a conflict procedure in pigeons to characterize anxiolytic drug activity: Evaluation of N-methyl-D-aspartate antagonists. Life Sci 1991;49:PL37-42.
34. 3H]PK 11195, by thermodynamic studies. Life Sci 1983;33:449-457.
35. Lipton SA, Rosenberg P. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994;330:613-622.
36. Malgouris C, Bardot F, Daniel M, et al. Riluzole, a novel antiglutamate, prevents memory loss and hippocampal neuronal damage in ischemic gerbils. J Neurosci 1989;9:3720-3727.
37. Mantz J, Chéramy A, Thierry AM, Glowinski J, Desmonts JM. Anesthetic properties of riluzole (54274 RP), a new inhibitor of glutamate neurotransmission. Anesthesiology 1992;76:844-848.
38. Mantz J, Laudenbach V, Lecharny JB, Henzel D, Desmonts JM. Riluzole, a novel antiglutamate, blocks GABA uptake by striatal synaptosomes. Eur J Pharmacol 1994;257:R7-R8.
39. Martin D, Thompson MA, Nadler JV. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol 1993;250:473-476.
40. McKee P, Fuller GN, Stevens DL. Riluzole in amyotrophic lateral sclerosis (letter). N Engl J Med 1994;331:273.
41. McRae KD. Riluzole in amyotrophic lateral sclerosis (letter). N Engl J Med 1994;331:273.
42. Meldrum B. Excitatory amino acids and anoxic/ischemic brain damage. Trends Neurosci 1985;8:47-48.
43. Mizoule J, Meldrum B, Mazadier M, et al. 2-amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory aminoacid neurotransmission: I. Anticonvulsant properties. Neuropharmacology 1985;24:767-773.
44. Murphy JR. Riluzole in amyotrophic lateral sclerosis (letter). N Engl J Med 1994;331:273.
45. Murphy NP, Cordier J, Glowinski J, Prémont J. Does protein kinase C exert a permissive effect on the N-Methyl-D-Aspartate-evoked rise in cytosolic calcium in striatal neurones? Eur. J. Neurosci (in press).
46. Plaitakis A, Smith Mandeli J, Yahr MD. Pilot trial of branched-chain aminoacids in amyotrophic lateral sclerosis. Lancet 1988;231:1015-1018.
47. Pratt J, Rataud J, Bardot F, et al. Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischemia. Neurosci Lett 1992;140:225-230.
48. Prenen GHM, Gwan F, Postema F, Zuiderveen F, Korf J. Cerebral cation shifts in hypoxic-ischemic brain damage are prevented by the sodium channel blocker tetrodotoxin. Exp Neurol 1988;99:118-132.
49. Rataud J, Bardone MC, Stutzmann JM, et al. Riluzole (PK 26124) induces discriminative stimuli in rats. Psychopharmacology (Suppl) 1989;96:373.
50. Rogawski MA. Riluzole in amyotrophic lateral sclerosis (letter). N Engl J Med 1994;331:273-274.
51. Romettino S, Ladzunski M, Gottesmann C. Anticonvulsant and sleep-waking influences of riluzole in a rat model of absence epilepsy. Eur J Pharmacol 1991;199:371-373.
52. Romo R, Chéramy A, Godeheu G, Glowinski J. In vivo presynaptic control of dopamine in the cat caudate nucleus: III. Further evidence for the implication corticostriatal glutamatergic neurons. Neuroscience 1980;1091-1099.
53. Rothman SM. Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death. J Neurosci 1984;4:1884-1891.
54. Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol 1986;19:105-111.
55. Rowland LP. Riluzole for the treatment of amyotrophic lateral sclerosis. To soon to tell? N Engl J Med 1994;330:636-637.
56. Samuel D, Blin O, Dusticier N, Nieoullon A. Effects of riluzole (2-amino-6-trifluoromethoxy benzothiazole) on striatal neurochemical markers in the rat, with special reference to the dopamine, choline, GABA, and glutamate synaptosomal high affinity uptake systems. Fundam Clin Pharmacol 1992;6:177-184.
57. Sanger DJ, Joly D. Effects of NMDA receptor antagonists and sigma ligands on the acquisition of conditioned fear in mice. Psychopharmacology 1991;104:27-34.
58. Stutzmann JM, Bohme GA, Gandólfo G, et al. Riluzole prevents hyperexcitability produced by the mast cell degranulating peptide and dendrotoxin I in the rat. Eur J Pharmacol 1991;193:223-229.
59. Stutzmann JM, Cintrat P, Laduron PM, Blanchard JC. Riluzole antagonizes the anxiogenic properties of the beta-carboline FG 7142 in rats. Psychopharmacology 1989;99:515-519.
60. Stutzmann JM, Doble A. Blockade of glutamatergic transmission and neuroprotection: The strange case of riluzole. In: Jolles G, Stutzmann JM, eds. Neurodegenerative Diseases. London (UK): Academic Press, 1994:205-214.
61. Stutzmann JM, Lucas M, Blanchard JC, Laduron PM. Riluzole, a glutamate antagonist, enhances slow wave and REM sleep in rats. Neurosci Lett 1988;88:195-200.
62. Testa D, Caraceni T, Fetoni V. Branched-chain amino acids in the treatment of aùyotrophic lateral sclerosis. J Neurol 1989;236:445-447.
63. Tsai D, Steel DJ, McPherson S, Taylor CA, Wood PL, Lehman J. PK 26124 is not a competitive antagonist at NMDA-type receptors. In: Excitatory Amino Acid Transmission. New York: Alan R. Liss, 1987:79-82.
64. Wahl F, Allix M, Plotkine M, Boulu RG. Effect of riluzole on focal cerebral ischemia in rats. Eur J Pharmacol 1993;230:209-214.
65. Woodbury DM. Applications to drug evaluations. In: Purpura DP, et al., eds. Experimental Models of Epilepsy. New York: Raven Press, 1972:557-583.
66. Yamasaki Y, Kogure K, Hara H, Ban H, Akaike N. The possible involvement of tetrodotoxin-sensitive ion channels in ischemic neuronal damage in the rat hippocampus. Neurosci Lett 1991;121:251-254.